Keeping Track: Merck & Co. In Spotlight With Welireg, Keytruda Approvals; FibroGen/AZ Roxadustat CRL Is No Surprise

 
• By Bridget Silverman
  
Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers